Jounce Therapeutics to Present at Upcoming Investor Conferences in September
August 28 2019 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Jounce management will present at three upcoming investor
conferences in September:
- Baird 2019 Global Healthcare Conference at
2:35 p.m. ET on Wednesday, September 4, 2019 in New York, NY
- 2019 Wells Fargo Healthcare Conference at 1:20
p.m. ET on Thursday, September 5, 2019 in Boston, MA
- H.C. Wainwright 21st Annual Healthcare
Conference at 9:10 a.m. ET on Monday, September 9, 2019 in
New York, NY
A live webcast of each presentation will be available by
visiting “Events & Presentations” in the Investors and Media
section of Jounce’s website at www.jouncetx.com. A replay of each
webcast will be archived for 30 days following the
presentations.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients through a biomarker-driven approach. Through
the use of its Translational Science Platform, Jounce first focuses
on specific cell types within the human tumor microenvironment to
prioritize targets, and then identifies related biomarkers designed
to match the right immunotherapy to the right patient. Jounce is
developing two clinical-stage programs as well as advancing and
building out its broad and wholly-owned discovery pipeline of
immuno-oncology targets, including those expressed on T-regulatory
cells, macrophages and stromal cells. Jounce’s lead product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS and is currently being assessed in a Phase 2
clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in
combination with future pipeline products, and Jounce has completed
enrollment in the JTX-4014 Phase 1 clinical trial. In addition,
Jounce has exclusively licensed worldwide rights to JTX-8064, a
LILRB2 receptor antagonist, to Celgene. For more information,
please visit www.jouncetx.com.
Investor Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Media Contact:Kathryn MorrisThe Yates
Network(914) 204-6412kathryn@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024